TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT04998422: Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of HG381 as Monotherapy in Patients With Advanced Solid Tumors

Sponsor: HitGen Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 57 pts

Competing Trials Overlap

2 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT04998422 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04998422 Rescue Dossier →